To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
49 Current news of Santhera Pharmaceuticals
rss
Santhera Joins EU-funded EndoStem Consortium in Preparation for Clinical Study with Omigapil in Congenital Muscular Dystrophies
04-12-2012
Santhera Pharmaceuticals announced its participation in the EndoStem Consortium, a pan-European partnership of 15 academic and industry teams. EndoStem is co-funded by the European Union and seeks to accelerate the development of effective therapies for muscular dystrophies. In collaboration ...
Santhera Obtains US Patent for Use of Catena in the Treatment of Muscular Dystrophies
08-26-2011
Santhera Pharmaceuticals announced that the United States Patent and Trademark Office granted patent protection for the use of idebenone (brand name Catena®) in the treatment of Duchenne Muscular Dystrophy and other muscular dystrophies. The patent in the United States is supplemented by a ...
Santhera Presents Data from 2-Year Open-Label Intervention Study with Catena in Duchenne Muscular Dystrophy
05-10-2011
Santhera Pharmaceuticals announced that it will present first analyses of the 2-year open-label study (DELPHI-E) evaluating Catena® for the treatment of Duchenne Muscular Dystrophy. The findings indicate that Catena® can slow the decline in respiratory function associated with patients as ...
Santhera Presents Positive Data from IONIA Open-Label Extension Study in Friedreich's Ataxia
05-06-2011
Santhera Pharmaceuticals announced that it will present positive data from an open-label extension study (IONIA-E) evaluating Catena® for the treatment of Friedreich's Ataxia. The findings indicate that Catena® can offer therapeutic benefit to pediatric patients by improving overall ...
Mode of Action for Santhera's Catena and its Relevance for Mitochondrial Disorders Revealed
04-05-2011
Santhera Pharmaceuticals announced the publication of details on the mode of action of idebenone (brand name Catena®) in PLoS ONE (Public Library of Sciences ONE). For the first time, a detailed biochemical pathway is described how idebenone can restore energy production in cells which are ...
Fipamezole Transition from Biovail completed
Program Well Advanced Towards Phase III
02-21-2011
Santhera Pharmaceuticals announced that the transition of the fipamezole program back from Biovail was successfully completed. Fipamezole is being developed as a potential first treatment of Dyskinesia in Parkinson's Disease. During its partnership with Santhera and in preparation for Phase ...
Santhera Obtains European Patent for Use of Omigapil for the Treatment of Congenital Muscular Dystrophy
12-07-2010
Santhera Pharmaceuticals announced that the European Patent Office granted patent protection for the use of omigapil for the treatment of Congenital Muscular Dystrophy until 2026. This group of severe, genetically determined neuromuscular diseases frequently affects infants or young children ...
Santhera Regains Full Rights to Fipamezole in North America
10-25-2010
Santhera Pharmaceuticals announced that as of January 2011 it regains the US and Canadian rights for fipamezole from Biovail Laboratories International, now a wholly-owned subsidiary of Valeant Pharmaceuticals International. Fipamezole is being prepared for Phase III development for the ...
Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
10-19-2010
Santhera Pharmaceuticals announced an exclusive license agreement with BioLineRx, covering Santhera's pre-clinical melanocortin-4 receptor (MC-4R) antagonist program currently in development for the treatment of cancer cachexia. Under the agreement, BioLineRx acquires all rights to develop, ...
Santhera Prepares for Pivotal Study with Omigapil in Congenital Muscular Dystrophy
10-01-2010
Santhera Pharmaceuticals informed about recent achievements and next steps in the clinical development program for omigapil as potential first treatment of Congenital Muscular Dystrophy (CMD). This severe, genetically determined neuromuscular disease frequently affects infants or young ...
